Wall Street rallied higher as investors digested upbeat earnings from big tech companies during the week. The Nasdaq gained 2 ...

Eli Lilly said on Thursday its experimental weight-loss pill met most criteria for the U.S. Food and Drug Administration's ...

Eli Lilly is partnering with Walmart to offer Zepbound through its direct-to-consumer program, making the popular medication ...

A $2.5 million grant from Lilly Endowment to the Indiana State Museum and Historic Sites will fund "a multi-year ...

Eli Lilly said on Tuesday it was collaborating with Nvidia to build a supercomputer to help with drug discovery and shorten ...

Eli Lilly reported strong earnings and raised guidance. Read more on what could be next for this biotech giant.

The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and spawning a ...

U.S. sales of Lilly’s weight-loss treatment Zepbound nearly tripled, to $3.57 billion, in the third quarter. Meanwhile, ...

Eli Lilly reported higher profit and raised its outlook on surging demand for its weight-loss drugs, sending its shares ...

Eli Lilly & Co. raised its full-year guidance as revenue from its blockbuster weight loss and diabetes drugs beat ...

Lilly now says it expects non-GAAP earnings from $23 to $23.70 a share this year, up from $21.75 to $23. The new guidance is ...

Eli Lilly remains a top GARP opportunity, with Q3 results reinforcing its robust business growth and dominance in incretin ...